Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Welcure Drugs & PharmaceuticalsBOM:524661 20 Return-on-Tangible-Equity is -205.57% as of Mar. 2026. GuruFocus rates BOM:524661 with a GF Score™ of 20/100. The stock has 5 warning signs investors should review. Among 113 Medical Distribution companies, Welcure Drugs & Pharmaceuticals ranks worse than 89.38% on this metric.
The historical rank and industry rank for Welcure Drugs & Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
BOM:524661'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -65.76 Med: 8.42 Max: 131.66
Current: -15.27
During the past 13 years, Welcure Drugs & Pharmaceuticals's highest Return-on-Tangible-Equity was 131.66%. The lowest was -65.76%. And the median was 8.42%.
BOM:524661's Return-on-Tangible-Equity is ranked worse than 89.38% of 113
companies
in the Medical Distribution industry
Industry Median: 8.78
vs BOM:524661: -15.27
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Welcure Drugs & Pharmaceuticals Return-on-Tangible-Equity Related Terms
Welcure Drugs & Pharmaceuticals Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524661 vs MCK, COR, CAH: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Welcure Drugs & Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Welcure Drugs & Pharmaceuticals Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Welcure Drugs & Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Welcure Drugs & Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -205.57% mean?
Welcure Drugs & Pharmaceuticals (BOM:524661) has a Return-on-Tangible-Equity of -205.57% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Welcure Drugs & Pharmaceuticals and its competitors. According to the industry distribution chart, Welcure Drugs & Pharmaceuticals ranks #101 out of 113 companies in the Medical Distribution industry, placing it in the top 89.4%.
Is Welcure Drugs & Pharmaceuticals' Return-on-Tangible-Equity too high?
Welcure Drugs & Pharmaceuticals' current Return-on-Tangible-Equity is -205.57%. Based on the distribution chart, Welcure Drugs & Pharmaceuticals ranks #101 out of 113 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Welcure Drugs & Pharmaceuticals has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Welcure Drugs & Pharmaceuticals' Return-on-Tangible-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Welcure Drugs & Pharmaceuticals ranks #101 out of 113 companies for Return-on-Tangible-Equity. This places Welcure Drugs & Pharmaceuticals in the lower half of its industry. The industry median Return-on-Tangible-Equity is 8.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.78, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Welcure Drugs & Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Welcure Drugs & Pharmaceuticals's current Return-on-Tangible-Equity is -205.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Welcure Drugs & Pharmaceuticals stock overvalued right now?
Welcure Drugs & Pharmaceuticals (BOM:524661) has a current Return-on-Tangible-Equity of -205.57%. The current Return-on-Tangible-Equity is -205.57%. Welcure Drugs & Pharmaceuticals' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Welcure Drugs & Pharmaceuticals (BOM:524661), the current Return-on-Tangible-Equity is -205.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Welcure Drugs & Pharmaceuticals Ltd is a pharmaceutical company. The company operates exclusively in a single business segment: the trading of medical products. The company's revenue is entirely derived from this segment, encompassing a range of activities from sourcing pharmaceutical products to facilitating their distribution in domestic and international markets.
20GF Score
Get the complete analysis for BOM:524661
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524661 has been successfully added to your 
